GSK Wins FDA Accelerated Approval for Lung Cancer Drug Nelkarmi
GSK received accelerated approval from the U.S. Food and Drug Administration for Nelkarmi in advanced ALK-positive lung cancer, clearing the company to launch the medicine in the United States. The drug came to GSK through its acquisition of Nuvalent.
The company is working to build a franchise in lung cancer, which is the leading cause of cancer death, and the approval adds to its oncology portfolio.
GSK reported revenue of 32.67 billion GBP in fiscal 2025. Its next earnings date is scheduled for Feb 3, 2027.